682 related articles for article (PubMed ID: 32504861)
21. Myeloablative Haploidentical Donor Hematopoietic Transplantation Using Post-Transplantation Cyclophosphamide and Antithymocyte Globulin.
El Fakih R; Nassani M; Rasheed W; Hanbali A; Almohareb F; Chaudhri N; Alsharif F; Alfraih F; Shaheen M; Alhayli S; Alkhaldi H; Alshaibani A; Alotaibi AS; Alahmari A; Alamer A; Tarig A; Youniss R; Albabtain AA; Alfayez M; Saad A; Ahmed SO; Alzahrani H; Aljurf M
Transplant Cell Ther; 2024 Mar; 30(3):312.e1-312.e7. PubMed ID: 38185379
[TBL] [Abstract][Full Text] [Related]
22. Assessment of Patient-Specific Human Leukocyte Antigen Genomic Loss at Relapse After Antithymocyte Globulin-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplant.
Wu H; Shi J; Luo Y; Yu J; Lai X; Liu L; Fu H; Ouyang G; Xu X; Xiao H; Huang H; Zhao Y
JAMA Netw Open; 2022 Apr; 5(4):e226114. PubMed ID: 35385089
[TBL] [Abstract][Full Text] [Related]
23. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
Vasu S; Geyer S; Bingman A; Auletta JJ; Jaglowski S; Elder P; O'Donnell LC; Bradbury H; Kitzler R; Andritsos L; Blum W; Klisovic R; Penza S; Efebera Y; Hofmeister C; Benson DM; Muthusamy N; Lozanski G; Devine SM
Biol Blood Marrow Transplant; 2016 Apr; 22(4):658-668. PubMed ID: 26743340
[TBL] [Abstract][Full Text] [Related]
24. Haploidentical donor stem cell transplantation had a lower incidence of bronchiolitis obliterans syndrome compared with HLA-matched sibling donor transplantation in patients with hematologic malignancies: Benefit from ATG?
Weng G; Fan Z; Xue H; Huang F; Xu N; Jin H; Yu S; Ye Z; Fan J; Xuan L; Liu Q
Front Immunol; 2022; 13():1036403. PubMed ID: 36389692
[TBL] [Abstract][Full Text] [Related]
25. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
Hamadani M; Blum W; Phillips G; Elder P; Andritsos L; Hofmeister C; O'Donnell L; Klisovic R; Penza S; Garzon R; Krugh D; Lin T; Bechtel T; Benson DM; Byrd JC; Marcucci G; Devine SM
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1422-30. PubMed ID: 19822302
[TBL] [Abstract][Full Text] [Related]
26. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1859-66. PubMed ID: 22863841
[TBL] [Abstract][Full Text] [Related]
27. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
28. Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience.
Butera S; Cerrano M; Brunello L; Dellacasa CM; Faraci DG; Vassallo S; Mordini N; Sorasio R; Zallio F; Busca A; Bruno B; Giaccone L
Ann Hematol; 2021 Jul; 100(7):1837-1847. PubMed ID: 33948721
[TBL] [Abstract][Full Text] [Related]
29. Unique Reduced-Intensity Conditioning Haploidentical Peripheral Blood Stem Cell Transplantation Protocol for Patients with Hematologic Malignancy.
Xu J; Miao W; Yuan H; Liu Y; Chen G; Wang H; Aizezi G; Qu J; Duan X; Yang R; Muhashi M; Han C; Ding L; Abulaiti N; Pang N; Zhang L; Jiang M
Transplant Cell Ther; 2023 May; 29(5):331.e1-331.e8. PubMed ID: 36775200
[TBL] [Abstract][Full Text] [Related]
30. Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience.
Zhou L; Gao ZY; Lu DP
Ann Hematol; 2020 Jun; 99(6):1389-1400. PubMed ID: 32291495
[TBL] [Abstract][Full Text] [Related]
31. Association between haploidentical hematopoietic stem cell transplantation combined with an umbilical cord blood unit and graft-
Yao D; Tian Y; Li J; Li B; Lu J; Ling J; Zheng D; Yao Y; Xiao P; Meng L; Hu S
Ther Adv Hematol; 2022; 13():20406207221134409. PubMed ID: 36324490
[TBL] [Abstract][Full Text] [Related]
32. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
34. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
[TBL] [Abstract][Full Text] [Related]
35. Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell Grafts.
Arcuri LJ; Hamerschlak N; Rocha V; Bonfim C; Kerbauy MN
Transplant Cell Ther; 2021 Sep; 27(9):782.e1-782.e7. PubMed ID: 34146733
[TBL] [Abstract][Full Text] [Related]
36. Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis.
Huang R; Tu S; Deng L; Kang Q; Song C; Li Y
Hematology; 2015 Jul; 20(6):313-9. PubMed ID: 25321657
[TBL] [Abstract][Full Text] [Related]
37. Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation.
Salas MQ; Atenafu EG; Law AD; Lam W; Pasic I; Chen C; Dong Hwan Kim D; Michelis FV; Gerbitz A; Lipton JH; Mattsson J; Kumar R; Viswabandya A
Transplant Cell Ther; 2021 May; 27(5):428.e1-428.e9. PubMed ID: 33965185
[TBL] [Abstract][Full Text] [Related]
38. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
Mohty M; Bay JO; Faucher C; Choufi B; Bilger K; Tournilhac O; Vey N; Stoppa AM; Coso D; Chabannon C; Viens P; Maraninchi D; Blaise D
Blood; 2003 Jul; 102(2):470-6. PubMed ID: 12649133
[TBL] [Abstract][Full Text] [Related]
39. Clinical Features of Chronic Graft-Versus-Host Disease Following Haploidentical Transplantation Combined with Infusion of a Cord Blood.
Tao T; Li Z; Chu XL; Zhu WJ; Xu Y; Wu DP; Ma X; Xue SL
Stem Cells Dev; 2019 Jun; 28(11):745-753. PubMed ID: 30977441
[TBL] [Abstract][Full Text] [Related]
40. Incidence, Risk Factors, Characteristics, and Outcome of Chronic Graft Versus Host Disease in Children Undergoing Haploidentical Peripheral Blood Stem Cell Transplant With Post-transplant Cyclophosphamide.
Arora S; Thakkar D; Upasana K; Yadav A; Rastogi N; Sharma PS; Yadav SP
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e44-e50. PubMed ID: 37983773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
